Gossamer Bio (NASDAQ:GOSS – Get Free Report) and Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Gossamer Bio and Coeptis Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $48.47 million | 0.82 | -$170.37 million | ($0.79) | -0.22 |
| Coeptis Therapeutics | $1.36 million | 190.97 | -$11.92 million | ($2.52) | -2.00 |
Institutional & Insider Ownership
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Gossamer Bio and Coeptis Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -324.82% | N/A | -96.10% |
| Coeptis Therapeutics | -810.04% | -92.29% | -73.52% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Gossamer Bio and Coeptis Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 4 | 3 | 0 | 2.11 |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Gossamer Bio presently has a consensus target price of $3.20, suggesting a potential upside of 1,779.04%. Given Gossamer Bio’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Coeptis Therapeutics.
Risk & Volatility
Gossamer Bio has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.
Summary
Gossamer Bio beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
